洛铂、顺铂联合药物治疗晚期肺癌的疗效对比研究

洛铂、顺铂联合药物治疗晚期肺癌的疗效对比研究
刘艳萍
【期刊名称】《实用癌症杂志》
【年(卷),期】2018(033)001
【摘要】Objective To evaluate the efficacy of combination therapy with lobaplatin and cisplatin in the treatment of advanced lung cancer.Methods Randomly selected 120 patients with lung cancer were divided into 6 groups:group A1(20 pa-tients)were treated with lobaplatin combined with docetaxel chemotherapy;group A2(20 patients)received cisplatin combined with docetaxel chemotherapy;group B1(20 patients)received lobaplatin combined with gemcitabine chemotherapy;group B2(20 patients)received cisplatin and gemcitabine chemotherapy;group C1(20 patients)received lobaplatin combined with etoposide chemotherapy;group C2(20 patients)received cisplatin combined with gemcitabine chemotherapy,completed at least 2 cycles of treatment.During the chemotherapy,anti-allergy,liver and stomach treatment were carried out,and the bone marrow suppression before,during and after chemotherapy was recorded.Results Effective rates of A1 group,B1 group,C1 group were 35%,30%, 50%,the disease control rates were 52%,75%,85%; effective rates of A2 group,B2 group and C2 group were 40%,45%, 60%,the disease control rate were 75%,80%,90%.The short-term effects of A1,B1 and C1 groups were not significantly differ-ent from those
of A2,B2 and C2 groups(P>0.05).The incidence of severe leukocyte and thrombocytopenia in group A 1,group B1 and group C1 was higher than those of group A2,B2 and C2,but the incidence of gastrointestinal digestive system reaction was low,and the difference was statistically
significant(P<0.05).Conclusion The clinical effects of lobaplatin and cisplatin com-bined with lung cancer are similar in recent years,but the toxicity and side effects of platinum and platinum are less than cispla-tin.%目的探讨洛铂顺铂联合药物治疗晚期肺癌的疗效对比.方法随机选取肺癌患者120例,分成6组:A1组患者20例,洛铂联合多西他赛方案化疗;A2组患者20例,顺铂联合多西他赛方案化疗;B1组患者20例,洛铂联合吉西他滨方案化疗;B2组患者20例,顺铂联合吉西他滨方案化疗;C1组患者20例,洛铂联合依托泊苷方案化疗;C2组患者20例,顺铂联合吉西他滨方案化疗,至少完成2个周期以上的治疗.化疗过程中,进行抗过敏预防和保肝护胃处理,记录化疗前、中、后骨髓抑制情况.结果 A1组、B1组、C1组患者有效率分别为35.0%、30.0%、50.0%,疾病控制率分别为52.0%、75.0%、85.0%;A2组、B2组、C2组有效率分别为40.0%、45.0%、60.0%,疾病控制率分别为75.0%、80.0%、90.0%.A1、B1、C1组的近期疗效与A2、B2、
C2组无统计学差异(P>0.05).A1组、B1组、C1组中重度白细胞、血小板降低的发生率比A2、B2、C2组高,但胃肠消化系统反应发生率要低,差异具有统计学意义(P<0.05).结论洛铂和顺铂联合药物治疗肺癌时,近期临床效果相似;但是洛铂对患者造成的毒副作用要比顺铂小.
【总页数】3页(P69-71)
【作者】刘艳萍
【作者单位】110044 沈阳市胸科医院
【正文语种】中文
【中图分类】R734.2
【相关文献】
1.依托泊苷联合洛铂与依托泊苷联合顺铂一线治疗广泛期小细胞肺癌的对比研究[J], 李芸;高珅;张学林;赵卫国
2.洛铂和顺铂治疗恶性胸腔积液的疗效、不良反应及对外周血循环肿瘤细胞影响对比研究 [J], 刘俊;魏树全;赵子文
3.顺铂与洛铂联合紫杉醇应用于宫颈癌辅助化疗的毒副反应对比研究 [J], 王琰;申沛
4.洛铂、顺铂联合药物治疗晚期肺癌的效果对比评价 [J], 梁靓
5.奈达铂和顺铂分别联合吉西他滨治疗晚期肺癌的对比研究 [J], 贺志隆
因版权原因，仅展示原文概要，查看原文内容请购买。